HNC664

N/A

Report date: 2022/06/28 10:23:41
NME

Base Information

Drug NameHNC664
Drug Alias NameHNC664HNC-664
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEctonucleotide pyrophosphatase/phosphodiesterase 2 inhibitors
TargetsEctonucleotide pyrophosphatase/phosphodiesterase 2
Therapy Area/IndicationsIdiopathic Pulmonary FibrosisPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGuangzhou Henovcom Bioscience Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesGuangzhou Henovcom Bioscience Co Ltd
Inactive CompaniesN/A
Active IndicationsIdiopathic Pulmonary FibrosisPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A